Dunkirk drug plant deal reset: ImmunityBio given new timeline, tougher terms

DUNKIRK, N.Y. — A long-stalled pharmaceutical manufacturing project in Dunkirk may finally be moving toward a restart, with a revised agreement setting new financial terms, deadlines, and hiring expectations for ImmunityBio.

According to Chautauqua County Industrial Development Agency CEO Mark Geise, the company has agreed to a revised lease with New York State that will have it pay $525,000 annually in rent for the state-owned facility on Lake Shore Drive.

The new deal marks a major shift from the symbolic $1 lease ImmunityBio inherited after taking over the failed deal tied to Athenex, which went bankrupt in 2023…

Story continues

TRENDING NOW

LATEST LOCAL NEWS